CTLA4 and cancer: After the discovery of the roles of checkpoint molecules such as PD-1, its ligand PD-L1, and CTLA-4, efforts have been redirected toward developing antibodies to inhibit their activity and release the patient's own immune system to fight cancer (22, 109).